5.3 Congestive Heart Failure & Shock
Key Takeaways
- Clinical signs of neonatal CHF include resting tachycardia (> 160-180 bpm), hepatomegaly (liver edge > 2-3 cm below costal margin), and feeding diaphoresis driven by sympathetic overactivity.
- Digoxin toxicity causes bradycardia (< 90-100 bpm) and vomiting, and its risk is critically potentiated by hypokalemia, requiring careful potassium monitoring during loop diuretic therapy.
- Dopamine exhibits dose-dependent receptor activity, whereas dobutamine is a selective beta-1 agonist that improves contractility and reduces afterload, making it ideal for cardiogenic shock.
Congestive Heart Failure & Shock
Congestive Heart Failure (CHF) and shock represent states of cardiovascular insufficiency where the heart cannot supply adequate oxygen and nutrients to meet the metabolic demands of the tissues. In the neonate, early recognition and tailored pharmacological support are critical to prevent multi-organ failure.
Congestive Heart Failure (CHF) in the Neonate
Unlike adults, neonatal CHF is rarely caused by ischemic coronary artery disease. Instead, it is typically driven by volume overload (left-to-right shunting lesions like VSD or PDA), pressure overload (obstructive lesions like Coarctation of the Aorta or Aortic Stenosis), or primary myocardial dysfunction (severe asphyxia, myocarditis, or sepsis).
Clinical Presentation
Neonatal symptoms of heart failure are subtle and relate to systemic and pulmonary venous congestion:
- Tachypnea and Respiratory Distress: Pulmonary edema leads to tachypnea (respiratory rate > 60 breaths/min), retractions, and grunting.
- Tachycardia: Rest heart rate > 160-180 bpm as a compensatory mechanism to maintain cardiac output (stroke volume is relatively fixed in neonates due to non-compliant myocardium).
- Hepatomegaly: Systemic venous congestion leads to liver enlargement. A liver edge > 2-3 cm below the right costal margin is a key clinical sign of right-sided venous congestion (peripheral edema is rare in neonates; fluid accumulation occurs in the liver, periorbital area, and lungs).
- Feeding Intolerance and Diaphoresis: Feeding is the neonatal equivalent of exercise. Sweating on the forehead during feeds (diaphoresis) is driven by sympathetic nervous system activation.
- Failure to Thrive: High metabolic demands combined with poor feeding leads to poor weight gain.
- Cardiomegaly: Demonstrated on chest X-ray as a cardiothoracic ratio > 60%.
Pharmacological Management of CHF
1. Digoxin (Lanoxin)
A positive inotrope and negative chronotrope.
- Mechanism: Inhibits the Na+/K+ ATPase pump in myocardial cell membranes. This increases intracellular sodium, which slows the sodium-calcium exchanger, raising intracellular calcium concentration and enhancing myocardial contractility. It also increases vagal tone, slowing conduction through the AV node and decreasing the heart rate.
- Dosing:
- A Total Digitalizing Dose (TDD) of 20-30 mcg/kg IV/PO is administered in divided doses over 24 hours (typically 1/2 of TDD, then 1/4, then 1/4 at 8-to-12-hour intervals).
- Maintenance dosing is 8-10 mcg/kg/day split twice daily (every 12 hours).
- Therapeutic Range: 0.5 to 2.0 ng/mL.
- Toxicity and Monitoring:
- Signs of toxicity: Bradycardia (HR < 90-100 bpm), feed refusal, vomiting, and arrhythmias (PR interval prolongation, heart block).
- Electrolyte Interactions: Hypokalemia increases digoxin binding to the Na+/K+ ATPase pump, significantly potentiating digoxin toxicity even at normal therapeutic levels. Hypomagnesemia also increases toxicity risk, whereas hyperkalemia decreases digoxin's efficacy.
2. Diuretics: Furosemide (Lasix)
A loop diuretic.
- Mechanism: Inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, promoting the excretion of sodium, chloride, potassium, water, and calcium.
- Dosing: 1-2 mg/kg per dose IV or PO.
- Side Effects: Hypokalemia, hyponatremia, hypochloremic metabolic alkalosis, and dehydration. Long-term use causes hypercalciuria, which can lead to nephrocalcinosis (calcium deposits in the kidneys) and osteopenia of prematurity.
3. Afterload Reduction: Captopril
An Angiotensin-Converting Enzyme (ACE) inhibitor. It blocks the conversion of angiotensin I to angiotensin II, causing systemic vasodilation. This reduces systemic vascular resistance (afterload), making it easier for the failing left ventricle to pump blood forward, reducing left-to-right shunting.
Neonatal Shock
Shock is a state of systemic hypoperfusion where oxygen delivery is insufficient to meet cellular metabolic needs, leading to cellular hypoxia, anaerobic metabolism, and lactic acidosis.
Classifications of Neonatal Shock
| Shock Type | Pathophysiology & Causes | Clinical Features | Initial Management |
|---|---|---|---|
| Hypovolemic | Loss of intravascular volume.<br/>Causes: Placental abruption, feto-maternal hemorrhage, twin-to-twin transfusion, subgaleal hematoma, capillary leak. | Pale, cool skin; capillary refill > 3 seconds; weak peripheral pulses; tachycardia; hypotension (late sign). | Urgent volume expansion: 10-20 mL/kg of Normal Saline or packed red blood cells over 10-20 minutes. |
| Cardiogenic | Primary myocardial pump failure.<br/>Causes: Perinatal asphyxia (myocardial ischemia), critical obstructive CHD (HLHS, aortic stenosis), arrhythmias (SVT). | Tachypnea, hepatomegaly, cardiomegaly, poor perfusion with stable or low BP. High central venous pressure. | Inotropic support (dobutamine). Avoid rapid fluid boluses, which can worsen pulmonary edema. |
| Septic (Distributive) | Inflammatory cascade causing vasodilation, venous pooling, and capillary leak.<br/>Causes: bacterial sepsis (GBS, E. coli). | Temperature instability, hyperdynamic (warm, flushed) or hypodynamic (cold, clammy) shock, lactic acidosis. | Broad-spectrum antibiotics, cautious fluid resuscitation, vasoactive support. |
Vasoactive and Inotropic Support
Vasoactive agents are titrated continuously to support perfusion and blood pressure.
1. Dopamine
An endogenous catecholamine that stimulates dopaminergic, beta-adrenergic, and alpha-adrenergic receptors in a dose-dependent manner.
- Dosing and Action:
- Low Dose (1-5 mcg/kg/min): Primarily stimulates dopaminergic receptors, causing vasodilation in renal, mesenteric, and coronary beds. (Note: clinical utility of "renal-dose" dopamine is controversial in neonates).
- Moderate Dose (5-10 mcg/kg/min): Stimulates beta-1 adrenergic receptors, increasing myocardial contractility (inotropy) and heart rate (chronotropy).
- High Dose (10-20 mcg/kg/min): Stimulates alpha-1 adrenergic receptors, causing systemic arterial vasoconstriction and raising systemic blood pressure.
2. Dobutamine
A synthetic catecholamine that acts directly on beta-1 adrenergic receptors with minor beta-2 and alpha-1 stimulation.
- Action: Increases myocardial contractility (inotropy) and stroke volume with less chronotropic (heart rate) effect than dopamine. It reduces systemic vascular resistance (afterload) through mild beta-2 mediated vasodilation.
- Clinical Use: The drug of choice for cardiogenic shock and myocardial dysfunction (e.g., post-asphyxia) where blood pressure is stable but cardiac output is low.
- Dosing: 5 to 20 mcg/kg/min.
3. Epinephrine
A potent agonist of alpha-1, beta-1, and beta-2 adrenergic receptors.
- Action: Significantly increases heart rate, stroke volume, systemic vascular resistance, and blood pressure.
- Clinical Use: Indicated for refractory septic shock or post-arrest stabilization.
- Dosing: 0.05 to 1.0 mcg/kg/min continuous infusion.
- Risks: Increases myocardial oxygen demand, causes severe peripheral vasoconstriction, can induce hyperglycemia and transient lactic acidosis.
A neonate with congestive heart failure is prescribed digoxin. Prior to administering a scheduled maintenance dose, the nurse notes the infant's heart rate is 85 beats per minute (bpm) and the infant has vomited twice. What is the priority nursing action?
A term infant who suffered severe perinatal asphyxia is exhibiting signs of cardiogenic shock with a low cardiac output but stable systemic blood pressure. Which inotropic agent is the most appropriate first-line choice to increase myocardial contractility and reduce ventricular afterload?
A neonate receiving long-term furosemide (Lasix) therapy for pulmonary overcirculation from a VSD is at risk for developing which of the following metabolic and electrolyte abnormalities?